Moderna, Inc. (MRNA)
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Moderna's COVID-Flu Vaccine Shows Stronger Immune Response Than Individual Shots, Late-Stage Trial Finds
Moderna on Monday said its combination COVID-19 and flu shot elicits a stronger immune response against both viruses than licensed vaccines on the market, promising findings for the mRNA company as it works to diversify into areas like influenza and cancer amid diminishing demand for coronavirus shots.
Moderna COVID/flu combo vaccine superior to separate shots in trial
Moderna said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial.
Moderna's combo COVID and flu vaccine works better than stand-alone shots on the market, study finds
Moderna Inc.'s MRNA, -2.38% experimental combination COVID and flu vaccine triggered better immune responses than stand-alone shots currently on the market, according to clinical trial data the company released Monday.
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. Moderna stock has risen this year.
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Moderna said its combination vaccine targeting Covid and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. The biotech company is the first to release positive phase three data on a Covid and flu combination shot, giving it a potential lead over rivals Pfizer and Novavax.
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial. "Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses," said Stéphane Bancel, Chief Executive Officer of Moderna.
Why Moderna Stock Is a No-Brainer Buy Right Now
Moderna is at an inflection point with the recent FDA approval of its RSV vaccine. The company could have more new products on the way with its promising late-stage pipeline.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
3 Reasons to Buy Moderna Stock
Moderna finally earned approval for a non-coronavirus vaccine. The company's cancer vaccine candidate looks very promising.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
